📗 Cite This Artifact
Synaptic Vesicle Trafficking Dysfunction Validation in Parkinson's Disease
Synaptic Vesicle Trafficking Parkinsons
Experiment Design: SVT-PD-001
Overview
This multi-phase study aims to validate the Synaptic Vesicle Trafficking Dysfunction Hypothesis in Parkinson's Disease by assessing vesicle dynamics in patient-derived neurons, correlating with genetic risk variants, and testing therapeutic interventions.
Hypothesis
Impaired synaptic vesicle trafficking is an upstream driver of dopaminergic neurodegeneration in PD, not merely a downstream consequence.
Study Design
Phase 1: iPSC-Derived Neuron Studies
Objective
Characterize synaptic vesicle dynamics in dopaminergic neurons derived from PD patients with different genetic backgrounds vs. healthy controls.
Methods
| Parameter | PD Cases | Controls |
|-----------|----------|----------|
| Total subjects | 30 | 15 |
| LRRK2 G2019S carriers | 10 | — |
| VPS35 D620N carriers | 5 | — |
| Idiopathic PD | 10 | — |
| Healthy controls | — | 15 |
| Age range | 50-75 years | 50-75 years |
Primary Endpoints
...
Synaptic Vesicle Trafficking Parkinsons
Experiment Design: SVT-PD-001
Overview
This multi-phase study aims to validate the Synaptic Vesicle Trafficking Dysfunction Hypothesis in Parkinson's Disease by assessing vesicle dynamics in patient-derived neurons, correlating with genetic risk variants, and testing therapeutic interventions.
Hypothesis
Impaired synaptic vesicle trafficking is an upstream driver of dopaminergic neurodegeneration in PD, not merely a downstream consequence.
Study Design
Phase 1: iPSC-Derived Neuron Studies
Objective
Characterize synaptic vesicle dynamics in dopaminergic neurons derived from PD patients with different genetic backgrounds vs. healthy controls.
Methods
| Parameter | PD Cases | Controls |
|-----------|----------|----------|
| Total subjects | 30 | 15 |
| LRRK2 G2019S carriers | 10 | — |
| VPS35 D620N carriers | 5 | — |
| Idiopathic PD | 10 | — |
| Healthy controls | — | 15 |
| Age range | 50-75 years | 50-75 years |
Primary Endpoints
Secondary Endpoints
Phase 2: Genetic Correlation
Objective
Correlate synaptic vesicle function with known PD genetic risk variants.
Genetic Variants to Assess
| Gene | Variant | Expected Effect |
|------|---------|-----------------|
| SV2C | rs1871678, rs6474359 | Altered vesicle filling |
| VPS35 | D620N | Impaired endosomal sorting |
| SYNJ1 | R258Q | Impaired endocytosis |
| DNAJC13 | R392H | Endosomal dysfunction |
Analysis
- Whole exome sequencing for all participants
- Polygenic risk score calculation
- Correlation with vesicle function parameters
Phase 3: Therapeutic Testing
Objective
Test whether enhancing synaptic vesicle trafficking improves dopaminergic neuron survival.
Compounds to Test
| Compound | Target | Dose | Duration |
|----------|--------|------|----------|
| R55 | Retromer stabilizer | 10 mg/kg IP | 4 weeks |
| Tetrabenazine | VMAT2 inhibitor | 25 mg/day PO | 4 weeks |
| DMSO (vehicle) | — | — | 4 weeks |
In vivo Model
- C57BL/6 mice, 8-10 weeks old, male
- MPTP-induced parkinsonism model (30 mg/kg IP, 5 days)
- Behavioral testing: cylinder, grid, rotarod
In vitro Model
- Primary midbrain cultures from E14.5 rat embryos
- Treatment with test compounds for 7 days
- Alpha-synuclein PFF addition (day 3)
Readouts
Phase 4: Biomarker Validation
Objective
Identify biomarkers for early detection of synaptic vesicle dysfunction in PD.
Candidate Biomarkers
| Biomarker | Source | Method |
|----------|--------|--------|
| SV2C | CSF | ELISA |
| VAMP2 | Plasma exosomes | Western blot |
| Synaptotagmin-1 | CSF | MSD |
| VMAT2 binding | Brain PET | [11C]DTBZ PET |
Validation Cohort
- 50 early-stage PD patients (Hoehn & Yahr 1-2)
- 50 healthy controls
- Longitudinal sampling at 0, 6, 12, 24 months
Statistical Analysis
Power Calculation
- 80% power to detect 30% difference in vesicle density
- Alpha = 0.05, two-sided
- Accounting for 20% dropout
Primary Analysis
- Mixed-effects model for repeated measures
- Covariates: age, sex, disease duration
- False discovery rate correction for multiple comparisons
Ethical Considerations
- IRB approval required for iPSC studies
- Informed consent for genetic testing
- Animal studies under IACUC protocol
Timeline
| Phase | Duration | Start | End |
|-------|----------|-------|-----|
| Phase 1 | 18 months | Month 1 | Month 18 |
| Phase 2 | 12 months | Month 12 | Month 24 |
| Phase 3 | 12 months | Month 18 | Month 30 |
| Phase 4 | 24 months | Month 24 | Month 48 |
Budget Estimate
| Item | Cost (USD) |
|------|------------|
| Personnel | $1,200,000 |
| iPSC generation | $400,000 |
| Animal studies | $300,000 |
| Biomarker assays | $200,000 |
| PET imaging | $250,000 |
| Misc | $150,000 |
| Total | $2,500,000 |
Expected Outcomes
Risk Mitigation
| Risk | Mitigation |
|------|------------|
| iPSC reprogramming failure | Use validated protocols, have backup lines |
| Insufficient biopsy material | Use hair follicles or blood for reprogramming |
| Compound toxicity | Dose-finding study in healthy mice first |
| Dropout | Build in 20% cushion in enrollment |
Cross-References
- [Parkinson's Disease](/diseases/parkinsons-disease) — Primary disease
- [VPS35 Gene](/genes/vps35) — VPS35 mutation
- [SNARE Proteins](/mechanisms/snare-protein-function) — Vesicle fusion
- [Synaptic Vesicles](/cell-types/synaptic-vesicle-neurons) — Synaptic function
- [Dopamine Transport](/mechanisms/dopamine-transport-parkinsons) — Dopamine release
- [Synuclein Pathology](/mechanisms/alpha-synuclein-pathology) — alpha-synuclein
- [MPTP Model](/models/mptp-parkinson-model) — Mouse model
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | experiments-synaptic-vesicle-trafficking-parkinsons |
| kg_node_id | None |
| entity_type | experiment |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-1903b32b50c7 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'experiments-synaptic-vesicle-trafficking-parkinsons'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-experiments-synaptic-vesicle-trafficking-parkinsons?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Synaptic Vesicle Trafficking Dysfunction Validation in Parkinson's Disease](http://scidex.ai/artifact/wiki-experiments-synaptic-vesicle-trafficking-parkinsons)
http://scidex.ai/artifact/wiki-experiments-synaptic-vesicle-trafficking-parkinsons